Treatment group:Oral sirolimus

2 trials

Sponsors

Ruijin Hospital, Shanghai Jiaotong University, School of Medicine, The Third Affiliated Hospital of Sun Yat-sen University

Conditions

Immune checkpoint inhibitors-induced liver injuryImmune-mediated Liver Injury from Checkpoint Inhibitors, ILICI

Early Phase 1

Pilot study on the second-line treatment of sirolimus for steroid-refractory immune checkpoint inhibitor-related liver injury

Active, not recruitingChiCTR2500105086

Ruijin Hospital, Shanghai Jiaotong University, School of MedicineImmune checkpoint inhibitors-induced liver injury

Start: 2025-07-01Updated: 2025-06-30

Sirolimus for the Treatment of Refractory Immune Checkpoint Inhibitor-Related Liver Injury: A Single-Arm Exploratory Study

Active, not recruitingChiCTR2600120097

The Third Affiliated Hospital of Sun Yat-sen UniversityImmune-mediated Liver Injury from Checkpoint Inhibitors, ILICI

Start: 2026-03-10Updated: 2026-03-16